Literature DB >> 25383671

Platelet transfusion: a clinical practice guideline from the AABB.

Richard M Kaufman, Benjamin Djulbegovic, Terry Gernsheimer, Steven Kleinman, Alan T Tinmouth, Kelley E Capocelli, Mark D Cipolle, Claudia S Cohn, Mark K Fung, Brenda J Grossman, Paul D Mintz, Barbara A O'Malley, Deborah A Sesok-Pizzini, Aryeh Shander, Gary E Stack, Kathryn E Webert, Robert Weinstein, Babu G Welch, Glenn J Whitman, Edward C Wong, Aaron A R Tobian.   

Abstract

BACKGROUND: The AABB (formerly, the American Association of Blood Banks) developed this guideline on appropriate use of platelet transfusion in adult patients.
METHODS: These guidelines are based on a systematic review of randomized, clinical trials and observational studies (1900 to September 2014) that reported clinical outcomes on patients receiving prophylactic or therapeutic platelet transfusions. An expert panel reviewed the data and developed recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. RECOMMENDATION 1: The AABB recommends that platelets should be transfused prophylactically to reduce the risk for spontaneous bleeding in hospitalized adult patients with therapy-induced hypoproliferative thrombocytopenia. The AABB recommends transfusing hospitalized adult patients with a platelet count of 10 × 109 cells/L or less to reduce the risk for spontaneous bleeding. The AABB recommends transfusing up to a single apheresis unit or equivalent. Greater doses are not more effective, and lower doses equal to one half of a standard apheresis unit are equally effective. (Grade: strong recommendation; moderate-quality evidence). RECOMMENDATION 2: The AABB suggests prophylactic platelet transfusion for patients having elective central venous catheter placement with a platelet count less than 20 × 109 cells/L. (Grade: weak recommendation; low-quality evidence). RECOMMENDATION 3: The AABB suggests prophylactic platelet transfusion for patients having elective diagnostic lumbar puncture with a platelet count less than 50 × 109 cells/L. (Grade: weak recommendation; very-low-quality evidence). RECOMMENDATION 4: The AABB suggests prophylactic platelet transfusion for patients having major elective nonneuraxial surgery with a platelet count less than 50 × 109 cells/L. (Grade: weak recommendation; very-low-quality evidence). RECOMMENDATION 5: The AABB recommends against routine prophylactic platelet transfusion for patients who are nonthrombocytopenic and have cardiac surgery with cardiopulmonary bypass. The AABB suggests platelet transfusion for patients having bypass who exhibit perioperative bleeding with thrombocytopenia and/or evidence of platelet dysfunction. (Grade: weak recommendation; very-low-quality evidence). RECOMMENDATION 6: The AABB cannot recommend for or against platelet transfusion for patients receiving antiplatelet therapy who have intracranial hemorrhage (traumatic or spontaneous). (Grade: uncertain recommendation; very-low-quality evidence).

Entities:  

Mesh:

Year:  2015        PMID: 25383671     DOI: 10.7326/M14-1589

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  158 in total

1.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

Review 2.  [Therapy with blood products].

Authors:  S Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-01-29       Impact factor: 0.840

3.  Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763).

Authors:  Matthew A Warner; Nilesh S Jambhekar; Salwa Saadeh; Eapen K Jacob; Justin D Kreuter; William C Mundell; Alberto Marquez; Andrew A Higgins; Nageswar R Madde; William J Hogan; Daryl J Kor
Journal:  Transfusion       Date:  2019-06-20       Impact factor: 3.157

4.  Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions.

Authors:  Seema Kacker; Evan M Bloch; Paul M Ness; Eric A Gehrie; Christi E Marshall; Parvez M Lokhandwala; Aaron A R Tobian
Journal:  Transfusion       Date:  2019-01-08       Impact factor: 3.157

5.  Effectiveness of Pooled Platelet Transfusion in Concordant and Discordant Groups among Dengue Patients.

Authors:  Amoolya Bhat; Vijaya Chowdappa; Smita Surendra Masamatti
Journal:  J Clin Diagn Res       Date:  2016-07-01

6.  Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia.

Authors:  Lise J Estcourt; Callum Ingram; Carolyn Doree; Sally Hopewell; Marialena Trivella; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-12-02

7.  Embryonic stem cells as sources of donor-independent platelets.

Authors:  Matthew C Canver; Daniel E Bauer; Stuart H Orkin
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

Review 8.  Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.

Authors:  Anja Baigger; Rainer Blasczyk; Constanca Figueiredo
Journal:  Transfus Med Hemother       Date:  2017-05-23       Impact factor: 3.747

9.  In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.

Authors:  M Shukla; U D S Sekhon; V Betapudi; W Li; D A Hickman; C L Pawlowski; M R Dyer; M D Neal; K R McCrae; A Sen Gupta
Journal:  J Thromb Haemost       Date:  2017-02       Impact factor: 5.824

10.  Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.

Authors:  Daniel V Runco; Cassandra D Josephson; Sunil S Raikar; Kelly C Goldsmith; Glen Lew; Melinda Pauly; Ross M Fasano
Journal:  Transfusion       Date:  2018-02-04       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.